exenatide

Five advancements in diabetes treatment to watch
Five advancements in diabetes treatment to watchThe healthcare industry continues to focus efforts on treatments that work better, and ideally are less expensive and less invasive for patients.
New data examines sustained glycemic control with exenatide once weekly vs. insulin glarginePost-hoc analysis found that, despite continued titration with insulin glargine, more diabetes patients achieved sustained glycemic control with exenatide once-weekly, according to data presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria.
FDA approves exenatide ER pen for diabetesBringing a new tool to the arsenal of medications to treat type 2 diabetes, FDA recently approved the only once-weekly injectable pen for adults with type 2 diabetes—exenatide extended-release for injectable suspension (AstraZeneca, Bydureon Pen).
GLP-1 targeted therapy may help diabetes patientsThe role of ophthalmologists will become increasingly more vital in the management of type 2 diabetes as the numbers of patients with the disease is projected to double by 2030. Exenatide may prove to be an important adjunct to current oral anti-diabetes drugs.
FDA approves first once-weekly pen for diabetesBringing a new tool to the arsenal of medications to treat type 2 diabetes, FDA recently approved the only once-weekly injectable pen for adults with type 2 diabetes.
Emerging therapies for treating type 2 diabetesType 2 diabetes mellitus presents multiple treatment dilemmas for prescribers and healthcare clinicians. The number of oral agents for treating diabetes has increased over the past decade, and the best treatment regimen for each patient often varies based on comorbid conditions and treatment goals. Hence, understanding the risks and benefits of each agent is vital. While the number of agents for treating type 2 diabetes mellitus continues to increase, prescribers and clinicians may struggle with the need to individualize care as a means to improve treatment outcomes.
Once weekly exenatide is an alternative treatment to daily basal insulinTypically, basal insulin is chosen as the add-on treatment in patients with severe hyperglycemia. However, it has been questioned whether it is the best option, according to research presented in June at American Diabetes Association 73rd Scientific Sessions, in Chicago.
Lower risk of heart failure and stroke with exenatide than with insulinIn patients with type 2 diabetes, treatment with exenatide has shown beneficial effects on cardiovascular risk factors. A recent study used the GE Healthcare database to evaluate the risk of heart failure, myocardial infarction, and stroke in 2,795 patients taking exenatide twice daily and in 51,547 patients taking insulin in routine clinical practice.
Patients treated with weekly exenatide have better glycemic control and weight loss than patients treated with insulin glargineA recent international, open-label, randomized, controlled study of patients with type 2 diabetes mellitus compared once-weekly exenatide to titrated insulin glargine.
FDA evaluates diabetes drugs for possible increased risk of pancreatitis, precancerous cellular changes of pancreas